{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:48:04Z","timestamp":1775674084765,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.nrleng.2026.501920","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:37:34Z","timestamp":1775669854000},"page":"501920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach"],"prefix":"10.1016","volume":"41","author":[{"given":"L.","family":"Mart\u00ednez-Vicente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gajate-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.L.","family":"Guerrero-Peral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Horga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guerrero-Sola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"\u00c1lvarez-Troncoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Restrepo-C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Goirigolzarri-Artaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mart\u00edn-Albarr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Valverde-Meg\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garc\u00eda-Pav\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mat\u00edas-Guiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gal\u00e1n-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2026.501920_bib0155","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","article-title":"Transthyretin familial amyloid polyneuropathy: an update","volume":"265","author":"Plante-Bordeneuve","year":"2017","journal-title":"J Neurol"},{"issue":"S2","key":"10.1016\/j.nrleng.2026.501920_bib0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","article-title":"Hereditary transthyretin amyloidosis overview","volume":"43","author":"Manganelli","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nrleng.2026.501920_bib0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTRgene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nrleng.2026.501920_bib0175","article-title":"Transthyretin familial amyloid polyneuropathy (TTR-FAP): parameters for early diagnosis","volume":"8","author":"Escolano-Lozano","year":"2017","journal-title":"Brain Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.nrleng.2026.501920_bib0180","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/CS20160413","article-title":"Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy","volume":"131","author":"Galant","year":"2017","journal-title":"Clin Sci"},{"key":"10.1016\/j.nrleng.2026.501920_bib0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.nrleng.2026.501920_bib0195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neurol.2016.08.007","article-title":"Familial amyloid polyneuropathy: when does it stop to be asymptomatic and need a treatment?","volume":"172","author":"Adams","year":"2016","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0200","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with Tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington-Cruz","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0215","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of Tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0220","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ene.13510","article-title":"Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"25","author":"Gundapaneni","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0230","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of Tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0235","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0240","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to Tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nrleng.2026.501920_bib0245","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.neurol.2018.01.085","article-title":"Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis: results from the phase 3 APOLLO study","volume":"174","author":"Adams","year":"2018","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.nrleng.2026.501920_bib0255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0260","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01960-9","article-title":"Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nrleng.2026.501920_bib0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13506129.2022.2126308","article-title":"Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response","volume":"30","author":"Monteiro","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0270","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with Tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plant\u00e9-Bordeneuve","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0275","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"issue":"S1","key":"10.1016\/j.nrleng.2026.501920_bib0280","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-10-S1-P6","article-title":"Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area","volume":"10","author":"Cortese","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nrleng.2026.501920_bib0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13506129.2022.2118043","article-title":"Impact of baseline polyneuropathy severity on Patisiran treatment outcomes in the APOLLO trial","volume":"30","author":"Quan","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.nrleng.2026.501920_bib0290","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic Patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0295","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/ene.15325","article-title":"Real-life experience with Inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: data from an early-access program in Italy","volume":"29","author":"Luigetti","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2026.501920_bib0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/WCO.0000000000000852","article-title":"Hereditary transthyretin amyloidosis: current treatment","volume":"33","author":"Adams","year":"2020","journal-title":"Curr Opin Neurol"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:37:48Z","timestamp":1775669868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2173580826000271"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.501920","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.501920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501920"}}